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Background: Abnormal microRNA (miRNA) expressions and promoter methylation of genes detected in sputum
may provide biomarkers for non-small lung cancer (NSCLC). Here, we evaluate the individual and combined analysis
of the two classes of sputum molecular biomarkers for NSCLC detection.
Results: We analyze expression of 3 miRNAs (miR-21, miR-31, and miR-210) and methylation of 3 genes (RASSF1A,
PRDM14, and 3OST2), which were previously identified as potential biomarkers for NSCLC, in sputum of a set of 117
stage I NSCLC patients and 174 cancer-free smokers. The results are validated in a different set of 144 stage I NSCLC
patients and 171 controls. The panel of 3 miRNA biomarkers has 81.5 % sensitivity and 85.9 % specificity; the panel
of 3 methylation biomarkers displays 82.9 % sensitivity and 76.4 % specificity for NSCLC detection. Integrated
analysis of 2 miRNAs (miR-31 and miR-210) and 2 genes (RASSF1A and 3OST2) yields higher sensitivity (87.3 %) and
specificity (90.3 %) compared with the individual panels of the biomarkers (P < 0.05). Combined analysis of all the 3
miRNAs and 3 genes does not have performance superior to that of the panel of 2 miRNAs and 2 genes (P > 0.05).
The performance of combined use of the two classes of biomarkers was confirmed in the validation set.
Conclusions: The integration of two different classes of biomarkers synergistically improves both the sensitivity and
the specificity for the early detection of NSCLC.
Keywords: Lung cancer, Sputum, MicroRNA, DNA methylation, DiagnosisBackground
Lung cancer is the number one cancer killer worldwide
[1]. Non-small cell lung cancer (NSCLC) accounts for
approximately 85 % of all lung cancer cases. Tobacco
smoking is the major cause of the disease. The overall 5-
year survival rate for stage I NSCLC patients who are
typically treated with surgery remains up to 83 %. In
contrast, only 5–15 % and less than 2 % of patients with
stage III and IV NSCLC are alive after 5 years [1]. These
statistics provide the primary rationale to improve the
early detection of NSCLC. Recently, a NCI-National
Lung Screening Trail (NLST) showed that the early
detection of lung cancer by using low-dose computed
tomography (LDCT) could significantly reduce the mor-
tality [2]. However, 25 % of smokers screened by LDCT* Correspondence: yunsu326@yahoo.com
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95 % are lastly determined to be false positives. Given
the high-false positive rate of LDCT, there is large
number of referrals for invasive biopsies and expensive
2-year multiple follow-up examinations that carry their
own morbidity and mortality. Therefore, it is clinically
imperative to develop a noninvasive and cost-effective
means that might be used alone or serve to supplement
LDCT findings for precisely identifying early stage
NSCLC.
Sputum is a noninvasively and easily accessible body
fluid that contains respiratory epithelial cells exfoliated
from the bronchial airways. Cytological study of sputum
can identify morphological abnormalities of bronchial
epitheliums and thus provides a noninvasive approach
for lung cancer detection. However, sputum cytology has
a poor sensitivity for detection of lung cancer at the
early stage. It has been well accepted that NSCLC
develops from a field defect characterized by anle is distributed under the terms of the Creative Commons Attribution 4.0
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repeated exposure of the airway of the smokers to the
tobacco-related carcinogens [3]. Kadara et al. showed
that the molecular alterations observed in the large
bronchial airway might reflect the altered changes
existed in lung tumors in the distal lung, regardless of
the anatomic location relative to the tumors [4]. Further-
more, Spira et al. [5] demonstrated that analysis of the
bronchial epitheliums of the airway of NSCLC patients
could detect the lung tumor-related molecular changes
and thus help diagnose lung cancer. Since sputum con-
tains exfoliated bronchial epithelial cells from the lungs,
examination of sputum might identify the molecular
abnormalities in the large bronchial airways that
reflected those existing in primary lung tumors [6].
Therefore, the analysis of sputum for the molecular
changes may provide a noninvasive and cost-effective
approach for lung cancer diagnosis.
CpG dinucleotides are in the promoter region of many
genes, particularly tumor suppressor genes (TSGs).
DNA methylation in the promoter region is frequently
associated with “gene silencing” [7]. Aberrant promoter
methylation can affect genes involved in cell-cycle con-
trol, DNA repair, cell adhesion, signal transduction,
apoptosis, and cell differentiation [7]. These epigenetic
changes are early events in carcinogenesis of NSCLC
and thus show great promise as biomarkers for lung
cancer early detection [8]. Various genes have been iden-
tified to display hypermethylation in lung tumor tissues
as opposed to noncancerous tissues [6, 9]. Importantly,
Belinsky et al. detected methylation of some TSGs in
sputum up to 3 years prior to the clinical diagnosis of
lung cancer [6, 9]. Hubers et al. recently demonstrated
that DNA methylation analysis of a panel of 3 genes
(RASSF1A, PRDM14, and 3OST2) in sputum produced a
sensitivity of 82 % and a specificity of 66 % for lung can-
cer detection [10]. Although the previous studies showed
that the 3 genes used together provided the most prom-
ising sputum methylation biomarkers for early stage
NSCLC, the sensitivity and specificity of the DNA
methylation biomarkers are not sufficient to be used in
the clinical settings for the early detection of NSCLC.
MicroRNAs (miRNAs) have important function in the
regulation of gene expression in various biological
processes [11]. Dysregulation of miRNAs plays crucial
roles in tumorigenesis [11]. Specific over- or under-
expressions of some miRNAs have been found to associ-
ate with lung tumor and thus open up a new field for
molecular diagnosis of NSCLC. Furthermore, endogen-
ous miRNAs are resistant to freeze-thaw action and sta-
bly exist in clinical samples, due to the small size and
relative resistance to nucleases [12]. We have for the first
time demonstrated that the miRNAs are reproducibly and
specifically measurable in sputum by using quantitativereverse transcription-PCR (qRT-PCR) [13], thus providing
a rationale for developing miRNAs as sputum biomarkers
for NSCLC. In addition, using a microarray-based plat-
form to profile expression of 818 mature miRNAs on
NSCLC tissues and the paired normal lung tissues, we
identified a set of 13 miRNAs (miRs-21, 31, 126, 139, 182,
200b, 205, 210, 375, 429, 486, and 708) that displayed
dysregulation in NSCLC [14–16]. We further showed 10
of the 13 miRNAs (miRs-21, 31, 126, 182, 200b, 205, 210,
375, 486, and 708) whose abnormal expressions in sputum
were related to lung cancer [14, 15]. Moreover, from the
miRNAs, we identified a panel of 3 sputum miRNA bio-
markers (miR-21, miR-31, and miR-210) with 82 % sensi-
tivity and 86 % specificity for NSCLC detection [17].
Although showing promising, the panel of 3 sputum
miRNA biomarkers also suffers from moderate sensitivity
and specificity for the early detection of lung cancer.
Since NSCLC is a heterogeneous disease and develops
from multifactorial molecular aberrations [4], the ana-
lysis of a single type of molecular changes (for example,
either dysregulation of miRNAs or gene promoter hyper-
methylation) may not achieve the performance required
to move forward for clinical application. Furthermore,
because dysregulation of the miRNAs and promoter
hypermethylation of TSGs have different and crucial
roles in lung tumorigenesis via numerous cellular path-
ways, we hypothesize that integrating the miRNA and
methylation biomarkers would have a synergistic effect
for NSCLC detection. Here, we evaluate the individual
and combined applications of the two classes of sputum




The study protocol was approved by the Institutional
Review Board of Jiangsu Province Hospital of Nanjing
University of Chinese Medicine. Written informed con-
sent forms were obtained from all participants. Final
diagnosis for NSCLC was made by using histopathologic
examinations of biopsy and surgical tissue specimens.
CT imaging was done by using a standard clinical proto-
col and read by radiologists. A positive result of CT was
determined according to “the Fleischner Society-
guidelines for management of small pulmonary nodules
detected on CT scans.” The surgical pathologic staging
was determined according to the TNM classification of the
International Union Against Cancer with the American
Joint Committee on Cancer and the International Staging
System for Lung Cancer. Histopathologic classification was
made according to the World Health Organization classifi-
cation. Control individuals were smokers with CT-
discovered PNs and 55–74 years old who had no prior
history of any cancer. All control subjects remained cancer
Su et al. Clinical Epigenetics  (2016) 8:109 Page 3 of 9free for a minimum 2-year follow-up. The demographic
and clinical characteristics of the recruited subjects, such as
stage and histological diagnosis, smoking history, size of
PN, and pulmonary functions, represented by forced
expiratory volume in 1 s (FEV1)/forced vital capacity (FVC)
were also collected.Sample collection, preparation, and sputum cytology
Sputum samples were collected from the participants
before they revived any treatment as previously de-
scribed [13–16, 18–27]. To reduce the percentage of oral
epithelial cells in the sputum, subjects were asked to
blow their nose, rinse their mouth, and swallow water to
minimize contamination of squamous cells from postna-
sal drip and saliva. Sputum samples were then coughed
in a sterile container and processed within 2 h. To fur-
ther minimize oral squamous cell contamination, opaque
or dense portions that looked different from saliva under
the inverted microscope were selected using blunt for-
ceps from expectorate. The samples were processed on
ice in 4 volumes of 0.1 % dithiothreitol (Sigma-Aldrich,
St. Louis, Mo) followed by 4 volumes of phosphate-
buffered saline (PBS) (Sigma-Aldrich). The cell suspen-
sion was filtered through 45 μm nylon gauzes (BNSH
Thompson, Scarborough, ON, Canada). Absolute cell
numbers and cell viability were quantitated by using a
hemacytometer with trypan blue. Two cytocentrifuge
slides were prepared from aliquots of cell suspension by
using a cytospin machine (Shandon, Pittsburgh, Pa) and
were then stained with the Papanicolaou staining tech-
nique [28]. Furthermore, a 400 differential nonsquamous
cell count was performed, and the differential cell count
was expressed as the percentage of the total nonsqua-
mous cells. A sputum sample was considered adequate if
lung macrophages or Curschmann spirals were present
on the slides [6, 28]. Positive sputum cytology for lung
cancer comprised carcinoma in situ and invasive
carcinoma.Analyzing DNA methylation in sputum by using qMSP
The isolation of DNA from sputum and the modification
were performed as previously described [10]. Quantitative
methylation specific PCR (qMSP) was done by using a
Lightcycler system (Roche Applied Science, Mannheim,
Germany) [10]. Hypermethylation markers for RASSF1A,
3OST2, and PRDM14 were selected, since the previous
study [10] suggested that the 3 genes used together pro-
vided the most promising sputum methylation biomarkers
for early stage NSCLC. Cycle threshold (Ct) values for
each gene were determined. We normalized Ct values of
the target genes in relation to that of myogenic differenti-
ation antigen 1 (MYOD1) [10, 29]. By using the formula:
2∧(Ct (MYOD1) −Ct (target gene)) × 100, we computedratio value to decide the relative level of methylation of
the genes in a given sample.
Assessing expressions of the miRNAs in sputum by using
qRT-PCR
We extracted RNA from sputum using a protocol estab-
lished in our previous reports [13–16, 21, 22]. We evalu-
ated the expressions of 3 miRNAs (miR-21, miR-31, and
miR-210) by qRT-PCR with Taqman miRNA assays (Ap-
plied Biosystems, Foster City, CA) [13–16, 21, 22]. We
calculated expression levels of the genes by using a com-
parative Ct method [13–17]. We normalized Ct values
of the target miRNAs in relation to that of U6 and deter-
mined relative expression of a miRNA in a given sample
using the equation 2 −ΔCt, where ΔCt = Ct (targeted
ncRNA) −Ct (U6) [16, 17, 30]. Two interplate controls
and one no-template control were carried along in each
experiment. All experiments were performed for at least
three times.
Statistical analysis
Based on one sample with binomially distributed out-
comes, we needed 45 NSCLC patients and 45 subjects
with benign PNs in a training set at 5 % significant level
with 80 % power to discover a panel of biomarkers. To
estimate sample size of a testing set for the validation of
the biomarkers, we used utilize area under the receiver-
operator characteristic (ROC) curve (AUC) analysis. The
AUC of H0 (the null hypothesis) was set at 0.5. H1 rep-
resented the alternative hypothesis. To have a high re-
producibility with adequate precision, we required 60
subjects per group in the testing set. With this sample
size, we would have 90 % power to detect an AUC of
0.75 at the 2 % significance level. Therefore, 117 stage I
NSCLC patients and 174 cancer-free smokers in a train-
ing set and 144 stage I NSCLC patients and 171 controls
in a testing set of this present study would provide
enough statistical power to analyze and validate the bio-
markers. We used a Wilcoxon rank-sum test to define
the difference between case and control group and com-
pute Spearman rank correlations among the molecular
changes and with clinical-pathologic variables. We also
used Pearson’s correlation analysis to assess the associ-
ation between changes of the genes and demographic
and clinical characteristics of the cancer cases or cancer-
free controls. We applied AUC to evaluate sensitivity
and specificity. We used the highest Youden’s J index
(sum of sensitivity and specificity − 1) to set up corre-
sponding cutoff value of each biomarker candidate [31].
We applied logistic regression [16] to identify composite
panels of biomarkers that could distinguish NSCLC pa-
tients from control subjects and compare the diagnostic
performances of the panels for lung cancer. The best
panel of biomarkers was selected and subsequently
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thresholds. We used the McNemar to evaluate the com-
plementary effect of the biomarkers to cytology for the
detection of NSCLC.
Results
The characteristics of subjects and sputum samples
We enrolled 1707 smokers who could cough sputum.
All of the sputum samples had deep lung macrophages
or Curschmann’s spiral and thus were suitable for the
cytological and molecular analysis [6, 32]. Among the
participants, 828 were NSCLC patients and 879 were
cancer-free smokers. Of the NSCLC cases, 261 had a
diagnosis of stage I NSCLC, 246 had stage II, and 321
had stage III–IV NSCLC. Since we proposed to assess
the individual and combined assessments of the two
classes of molecule changes for lung cancer detection at
the early stage, we only used sputum of the stage I
NSCLC patients in this study. From the 879 cancer-free
smokers, we selected 345 smokers with benign PNs as
controls in this study. The 261 stage I lung cancer pa-
tients and 345 smokers with benign PNs were split into
a training set and an internal testing set. The training set
included 117 cancer cases and 174 smokers with benign
PNs (Table 1). The 117 stage I lung cancer patients had
a median age of 66.5 years. Ninety-three (79.5 %) were
men. Sixty-three (53.8 %) NSCLC patients were diag-
nosed to have adenocarcinoma (AC), and 54 (46.2 %)
have squamous cell carcinoma (SCC). All the lung can-
cer patients were smokers with a median of 45.8 pack-
years of smoking. The 174 cancer-free controls were
smokers with a median of 44.7 pack-years of smoking, of
whom, 138 (79.3 %) were men. The cancer-free smokers
had granulomatous inflammation (n = 84), nonspecific
inflammatory changes (n = 51), or lung infections (n =
39). The testing (validation) set comprised 144 stage I
NSCLC patients and 171 smokers with benign PNsTable 1 Characteristics of a training set of stage I NSCLC patients an
NSCLC cases (n = 117)




Pack-years 45.83 (range, 6–148)
FEV1/FVC 0.48–0.73
Nodule size (cm) 3.23 (SD, 1.62)
Stage, all are stage I
Histological type
Adenocarcinoma (AC) 63
Squamous cell carcinoma (SCC) 54
Abbreviations: NSCLC non-small cell lung cancer, SD standard derivation, FEV1/FVC fo(Table 2). The NSCLC patients had a median age of
66.3 years. One hundred fourteen (79.2 %) were men.
Seventy-eight (54.2 %) NSCLC patients had AC, and 66
(45.8 %) had SCC. The NSCLC patients had a median of
44.4 pack-years of smoking. The 171 cancer-free subjects
had a median age of 65.2 years and a median of 43.3
pack-years of smoking. One hundred thirty-five (78.9 %)
were men. The cancer-free smokers had granulomatous
inflammation (n = 99), nonspecific inflammatory changes
(n = 51), or lung infections (n = 21). Because chronic ob-
structive pulmonary disease (COPD) could be present in
about 60 % of lung cancer patients and impact molecu-
lar profiles in sputum, we used COPD as additional
matching criteria for the smokers. COPD was classified
using the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) criteria with GOLD 2 (50 % ≤ FEV1 <
80 % predicted) or greater indicative of airflow obstruc-
tion [33]. No significant difference of the age, FEV1/
FVC or COPD, and smoking status was found between
the NSCLC patients and the smokers with benign PNs
(All P > 0.05), except size of PNs (Tables 1 and 2). Fur-
thermore, there was no difference of the number of dif-
ferent cell types in sputum samples of the lung cancer
patients versus the smokers with benign PNs (Additional
file 1: Table S1).
Promoter methylation of the 3 genes in sputum had a
significantly different level between NSCLC patients and
smokers with benign PNs
The analysis of RASSF1A, 3OST2, and PRDM14 for the
DNA hypermethylation was successfully performed in all
the sputum samples. The methylation status of the 3
genes was significantly elevated in the NSCLC cases
compared with the smokers with benign PNs in the
training set (all P < 0.05). As shown in Table 3, the indi-
vidual genes exhibited AUC values of 0.68–0.69, produ-
cing 45.3 to 59.3 % sensitivities and 77.3 to 86.2 %d smokers with benign pulmonary nodules
Controls (n = 174) P value




44.67 (range, 5–115) 0.34
0.44–0.67 0.12
2.25 (SD, 1.04) <0.01
rced expiratory volume in 1 s/forced vital capacity
Table 2 Characteristics of a testing set of stage I NSCLC patients and smokers with benign pulmonary nodules
NSCLC cases (n = 144) Controls (n = 171) P value




Pack-years 44.38 (range, 6–169) 43.26 (range, 5–119) 0.35
FEV1/FVC 0.47–0.53 0.43–0.84 0.08
Nodule size (cm) 3.26 (SD, 1.38) 2.17 (SD, 0.98) <0.01
Stage, all are stage I
Histological type
Adenocarcinoma (AC) 78
Squamous cell carcinoma (SCC) 66
Abbreviations: NSCLC non-small cell lung cancer, SD standard derivation, FEV1/FVC forced expiratory volume in 1 s/forced vital capacity
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of the 3 genes in combination generated a higher AUC
(0.79) compared with each individual one (all P < 0.01)
(Table 3). The DNA methylation of the 3 genes did not
exhibit special association with a histological type of the
NSCLC, size of PN, age, COPD status, and gender of the
participants (all P > 0.05). Furthermore, the panel of 3
genes created 82.9 % sensitivity and 76.4 % specificity for
the early detection of NSCLC. Our present study con-
firmed the previous finding [10] that the 3 genes could
be potential methylation biomarkers for lung cancer
detection.
The 3 miRNAs displayed a considerably different level in
sputum between NSCLC patients and smokers with
benign PNs
The 3 miRNAs had a significantly higher expression
level in sputum of the NSCLC patients compared with
the control individuals (all P < 0.05). Furthermore, the
individual miRNAs revealed AUC values of 0.76–0.84,
resulting in 61.7 to 76.6 % sensitivities and 70.9 to
81.9 % specificities for the early detection of NSCLC
(Table 4). Combined analysis of the 3 miRNAs produced
0.89 AUC (Table 4). Subsequently, the analysis of the 3
miRNAs together generated 81.5 % sensitivity and
85.9 % specificity for NSCLC detection. The expression
of miR-21 in sputum was closely associated with ACTable 3 DNA hypermethylation of 3 genes in sputum of a training
pulmonary nodules
Genes AUC (95 % CI) S
RASSF1A 0.68 (0.56 to 0.79) 4
3OST2 0.69 (0.60 to 0.78) 4
PRDM14 0.69 (0.58 to 0.79) 5
Combined use of the 3 genes 0.79 (0.72 to 0.88) 8
Abbreviations: NSCLC non-small cell lung cancer, AUC the area under receiver opera(P < 0.05), whereas miR-210 was related to SCC (P <
0.05). The changes of the miRNAs were associated
with size of PNs (P < 0.05). However, overall, the
panel of 3 sputum miRNA biomarkers did not show
special association with a histological type of the
NSCLC, size of PN, age, COPD status, and gender of
the participants (all P > 0.05). The results generated
from this current study confirmed our previous dis-
covery [17] that the 3 miRNAs would be potential
sputum biomarkers for lung cancer.
Integrated analysis of 2 miRNA and 2 DNA methylation
biomarkers in sputum has a synergistic effect for lung
cancer early detection
We used logistic regression models with constrained pa-
rameters as in least absolute shrinkage and selection op-
erator (LASSO) and AUCs to determine performance of
different patterns of combining the 3 miRNA and 3
DNA methylation biomarkers for lung cancer detection.
From the 6 genes, 2 miRNAs (miR-31 and miR-210) and
2 genes (RASSF1A and 3OST2) were selected as the best
biomarkers (all P < 0.001). Incorporated use of the 4 bio-
markers produced a higher AUC (0.93) (Fig. 1), as com-
pared with the panel of 3 miRNA biomarkers (0.89) or
the panel of methylation biomarkers (0.79) used alone
(P < 0.05). Furthermore, the use of the 4 biomarkers to-
gether generated 87.3 % sensitivity and 90.4 % specificityset of stage I NSCLC patients and smokers with benign
ensitivity (95 % CI) Specificity (95 % CI) P value
5.3 (32.56 to 56.23) 86.2 (75.38 to 90.56) <0.001
9.3 (36.58 to 59.59) 84.5 (72.15 to 87.29) <0.001
9.3 (47.40 to 68.73) 77.3 (65.5 to 85.16) <0.001
2.9 (71.97 to 90.82) 76.4 (64.91 to 85.60) <0.001
ting characteristic curve, CI confidence interval
Table 4 The expression of 3 miRNAs in sputum of a training set of stage I NSCLC patients and smokers with benign pulmonary nodules
miRNAs AUC (95 % CI) Sensitivity (95 % CI) Specificity (95 % CI) P value
miR-31 0.76 (0.70 to 0.83) 61.66 (55.35 to 67.68) 81.86 (76.23 to 86.83) <0.001
miR-21 0.80 (0.72 to 0.86) 79.47 (72.38 to 82.94) 70.98 (65.48 to 77.46) <0.001
miR-210 0.84 (0.78 to 0.90) 76.58 (68.35 to 80.13) 81.16 (75–23.37 to 86.18) <0.001
Combined use of 3 miRNAs 0.89 (0.85 to 0.94) 81.48 (68.5 to 90.75) 85.91 (72.41 to 94.25) <0.001
Abbreviations: AUC the area under receiver operating characteristic curve, CI confidence interval
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(miR-31 and miR-210) and 2 TSGs (RASSF1A and
3OST2) yielded higher sensitivity and specificity com-
pared with the panel of 3 miRNA biomarkers and the
panel of 3 methylation biomarkers used alone (all P <
0.05) (Table 5). Furthermore, the combined use of all the
6 biomarkers (3 miRNA and 3 methylation biomarkers)
did not produce higher sensitivity and specificity com-
pared with the panel of the 4 biomarkers (2 miRNAs
and 2 genes) (P > 0.05). In addition, Pearson’s correlation
analysis indicated that the estimated correlations among
levels of the 4 molecular biomarkers were very low (all
P > 0.05), implying that the integration of the different
classes of biomarkers might have complementary classi-
fication. Moreover, sputum cytology had 46.2 % sensitiv-
ity and 89.7 % specificity. The combined use of the 4
sputum biomarkers had a higher sensitivity (P < 0.01)
and a similar specificity compared with sputum cytology
(P = 0.46). However, the addition of the cytology study in
the biomarker panel did not improve the diagnostic effi-
ciency for lung cancer detection. Overall, the panel of
the 4 biomarkers had no special association with a histo-
logical type of the NSCLC, age, COPD status, and gen-
der of the participants (all P > 0.05). In addition, the
combined use of the 4 biomarkers showed a similar
accuracy for the detection of NSCLC in PNs <10 mm
versus PNs >10 mm.
Validating the synergistic effect of combined application
of the miRNA and DNA methylation biomarkers for lung
cancer detection
The optimized panel of the 4 sputum biomarkers con-
sisting of 2 miRNAs with elevated expression and 2
genes with DNA methylation was validated in a testing
cohort in a blinded fashion using the thresholds estab-
lished in the above training set. The biomarker panel
had 87.5 % sensitivity and 89.5 % specificity for lung
cancer detection. Furthermore, sputum cytology showed
45.8 % sensitivity and 90.1 % specificity. The 4 bio-
markers used in combination displayed a higher sensitiv-
ity (P < 0.01) and a similar specificity (P = 0.45) than did
sputum cytology. Therefore, the results created from the
validation set of samples confirmed the potential of inte-
grated analysis of the two classes of molecular changes
as a sputum assay for NSCLC detection.Discussion
Sputum is the most easily and noninvasively obtained
clinical sample containing bronchial epithelial cells exfo-
liated from the lungs. Molecular analysis of sputum for
lung cancer detection would be practically useful when
diagnostic biomarkers are appropriately identified. The
analysis of DNA methylation of a panel of 3 genes
(RASSF1A, 3OST2, and PRDM14) in sputum produced a
sensitivity of 82 % and a specificity of 66 % for lung can-
cer detection [10]. The 3 genes have been shown as the
most capable methylation biomarkers in sputum for the
diagnosis of lung cancer at the early stage [10]. Further-
more, we have identified a panel of 3 sputum miRNA
biomarkers (miR-21, miR-31, and miR-210) with 82 %
sensitivity and 86 % specificity for NSCLC [17]. This
present study demonstrates that the diagnostic perform-
ance of the sputum molecular biomarkers for lung can-
cer could be validated in a different set of sputum
samples. Furthermore, the biomarkers developed in
White Americans and African Americas are confirmed
in a geographically independent cohort (Chinese popula-
tion) and further imply the usefulness of the methylation
and miRNA-based biomarkers for NSCLC detection.
Since lung cancer is a heterogeneous disease featuring
field defects in the airway of smokers, a single class of
biomarkers might not achieve the sensitivity and specifi-
city required to move forward for clinically detecting
NSCLC. Indeed, although exhibiting promising, the use
of either the miRNA biomarker panel or the methylation
biomarker panel has limited diagnostic value, due to the
moderate sensitivity (81.5–82.9 %) and specificity (76.4–
85.9 %). DNA promoter hypermethylation play crucial
roles in the development and progression of cancer
through transcriptionally silencing TSGs [3]. In contrast,
miRNAs directly repress cancer-associated genes
through binding to sites within coding and untranslated
regions of mRNAs of the targets and hence contribute
to tumorigenesis [11]. Therefore, the miRNAs and DNA
methylations have highly and actively different functions
in carcinogenesis. Given the heterogeneous nature of
lung cancer and the numerous cellular pathways in-
volved, we hypothesize that integrating the miRNA and
DNA methylation biomarkers may improve the perform-
ance of the sputum assay for lung cancer detection. Our
current data suggests that the combined analysis of the
Fig. 1 Combined analysis of miRNA and DNA methylation
biomarkers in sputum has a synergistic effect for lung cancer
detection. a ROC curve of a panel of 3 miRNA biomarkers (miR-21,
miR-31, and miR-210) shows an AUC of 0.89 for differentiating
NSCLC patients from smokers with benign pulmonary nodules in
terms of sensitivity and specificity. b A panel of 3 DNA methylation
biomarkers (RASSF1A, 3OST2, and PRDM14) creates an AUC of 0.79 for
distinguishing NSCLC patients from the cancer-free smokers. c The
integration of 2 miRNAs (miR-31 and miR-210) and 2 TSGs (RASSF1A
and 3OST2) yields 0.93 AUC, which is statistically higher than that of
the panel of 3 miRNA biomarkers and the panel of 3 methylation
biomarkers (P < 0.05)
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diagnostic performance compared with a single type of
the molecular biomarkers used alone. Furthermore, thecorrelations among the changes of the miRNAs and pro-
moter methylation of the TSGs are very low, supporting
that the diagnostic vales of the two classes of molecular
alterations could be complementary to each other.
Therefore, the observation confirms our hypothesis. In
addition, the finding that the panel of sputum bio-
markers was not associated with a particular histologic
type of NSCLC substantiates the utility for predicting
lung cancer. Moreover, the combined use of the miRNA
and DNA methylation biomarkers had a comparable
diagnostic performance NSCLC in PNs <10 mm versus
PNs >10 mm. The integrated biomarkers would be prac-
tical to use, since accurately identifying NSCLC among
individuals with PNs <10 mm is one of the most clinic-
ally challenging [2].
Dysregulation of miR-31 was observed in various types
of cancer disease, including colorectal, head-and-neck,
and esophageal tumors [34]. The examination of serum
miR-210 expressions could help identify diffuse large B
cell lymphoma and pancreatic and lung cancers [35–37].
Epigenetic inactivation of the RASSF1 promoter region
is one of the earliest molecular events in lung tumori-
genesis [38, 39]. Furthermore, methylation of RASSF1A
is one of the major biomarker with increased risk of lung
cancer [40]. 3OST2 undergoes frequent promoter
methylation in various tumors [41–43], including lung
cancer [10]. This study extends the previous findings by
demonstrating that integrated analysis of the 4 molecu-
lar changes could be a potentially useful and efficient ap-
proach for lung cancer early detection.
The study does have some limitations. (i) Ideal bio-
markers should be very highly sensitive and specific for
NSCLC detection at the early stage. However, the com-
bined use of the two types of molecular biomarkers,
whereas promising, does not possess the required diag-
nostic discrimination for routine clinical application. In
the future, we should identify additional miRNA or
DNA methylation biomarkers that can be added to the
current ones so that the diagnostic efficacy of the spu-
tum assay could be improved. Furthermore, we have
shown that the assessment of numerical DNA copy-
number changes of genes or chromosomal aneusomy in
sputum could help diagnose early stage lung cancer
[24–27, 44–46]. Integrated assessment of the miRNAs
and DNA methylation with the genomic and chromo-
somal changes would also improve the early detection
of lung cancer. (ii) The objective of this project is to
evaluate the individual and combined applications of
the two classes of sputum biomarkers for the early
detection of lung cancer. We do not test the bio-
markers in the sputum samples of patients diagnosed
with advanced stage of NSCLC. However, we will
analyze the biomarkers in patients with different
stages of NSCLC to determine if there is correlation
Table 5 The performance of individual and combined applications of the two classes of sputum biomarkers for lung cancer detection
Biomarkers AUC (95 % CI) Sensitivity (95 % CI) Specificity (95 % CI) P value
The panel of the 3 miRNA biomarkers 0.89 (0.82 to 0.93) 81.50 (68.57 to 90.75) 85.91 (72.41 to 93.25) <0.001
The panel of the 3 DNA methylation biomarkers 0.79 (0.72 to 0.87) 82.9 (71.97 to 90.82) 76.43 (64.91 to 85.60) <0.001
Combined analysis of the two classes of sputum biomarkers 0.93 (0.89 to 0.96) 87.34 (77.95 to 93.76) 90.35 (80.12 to 96.37) <0.001
Abbreviations: NSCLC non-small cell lung cancer, AUC the area under receiver operating characteristic curve, CI confidence interval
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whether the biomarkers could be used to predict out-
come of the disease. (iii) The early detection of
NSCLC using LDCT followed by appropriate treat-
ments can significantly reduce lung cancer mortality
in smokers [2]. LDCT is now recommended for lung
cancer screening in smokers. Yet LDCT has a low
specificity for the early detection of lung cancer, pre-
senting a major clinical challenge [2]. The develop-
ment of the biomarkers for specifically identifying
NSCLC in a LDCT screening positive setting will re-
duce lung cancer mortality by sparing smokers with
benign PNs from invasive and expense multiple
follow-up examinations and facilitating effective treat-
ments to be instantly initiated for NSCLC [2]. How-
ever, cases and controls used in this study were
recruited from the hospital-based patients with CT-
discovered PNs. The participants might not well rep-
resentative of the smokers in LDCT screening setting
for lung cancer. We will perform a prospective trial
to determine if the analysis of the sputum biomarkers
could be used as an effective high-throughput screen-
ing for specifically identifying NSCLC in a LDCT
screening positive setting among smokers. (iv) The
number of females enrolled in the study is signifi-
cantly lower than the number of males. In the future,
we will perform a prospective study to recruit appro-
priate number of females and further evaluate if a
gender effect can be observed using these biomarkers.
Furthermore, the results were based on a Chinese
population with PNs. We will investigate if there are
ethnicity-specific associations of the panel of multifa-
ceted biomarkers with other ethnic groups for the
early detection of lung cancer.
Conclusions
Given the heterogeneous nature of NSCLC that develops
from multifactorial molecular aberrations, we have for
the first time demonstrated that the integration of DNA
methylation and miRNA biomarkers could provide a
more efficient approach for the early detection of lung
cancer. Nonetheless, a large multicenter clinical project
to further validate the full utility of the combined
approach is required before the biomarkers could be
adopted in routine clinical setting.Additional file
Additional file 1: Table S1. Differential cell percentages of stage I
non-small cell lung (NSCLC) patients and smokers with benign pulmonary
nodules. (XLS 25 kb)
Funding
This study was supported in part by a grant for cancer research from Jiangsu
Province Hospital of Nanjing University of Chinese Medicine.
Availability of data and materials
Not applicable.
Authors’ contributions
YS was responsible for the concept, design, and conduct of the study and
manuscript preparation. HF assisted in the analysis of data. FJ assisted in the
manuscript preparation. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study was approved by Nanjing University of Chinese Medicine
Institutional Review Board and adhered to the Declaration of Helsinki, and all
patients provided written informed consent.
Author details
1Department of Surgery, Jiangsu Province Hospital of Nanjing University of
Chinese Medicine, 138 Xianlin Road, Nanjing 210023, China. 2Department of
Epidemiology, University of Maryland School of Medicine, Baltimore, MD,
USA. 3Department of Pathology, University of Maryland School of Medicine,
Baltimore, MD, USA.
Received: 25 July 2016 Accepted: 5 October 2016
References
1. Cancer facts & figures 2012. American Cancer Society (ACS). Journal of
Consumer Health on the Internet. 2012; 16:366–367.
2. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al.
Reduced lung-cancer mortality with low-dose computed tomographic
screening. N Engl J Med. 2011;365:395–409.
3. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung
cancer. Nat Rev Cancer. 2004;4:707–17.
4. Kadara H, Wistuba II. Field cancerization in non-small cell lung cancer:
implications in disease pathogenesis. Proc Am Thorac Soc. 2012;9:38–42.
5. Brody JS, Spira A. State of the art. Chronic obstructive pulmonary disease,
inflammation, and lung cancer. Proc Am Thorac Soc. 2006;3:535–7.
6. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, et al. Promoter
hypermethylation of multiple genes in sputum precedes lung cancer
incidence in a high-risk cohort. Cancer Res. 2006;66:3338–44.
7. Leonhardt H, Cardoso MC. DNA methylation, nuclear structure, gene
expression and cancer. J Cell Biochem Suppl. 2000;35:78–83.
8. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson
E, et al. Aberrant methylation of p16 (INK4a) is an early event in lung cancer
Su et al. Clinical Epigenetics  (2016) 8:109 Page 9 of 9and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A.
1998;95:11891–6.
9. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA,
et al. Aberrant promoter methylation in bronchial epithelium and sputum
from current and former smokers. Cancer Res. 2002;62:2370–7.
10. Hubers AJ, Heideman DA, Burgers SA, Herder GJ, Sterk PJ, Rhodius RJ, et al.
DNA hypermethylation analysis in sputum for the diagnosis of lung cancer:
training validation set approach. Br J Cancer. 2015;112:1105–13.
11. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell.
2005;122:6–7.
12. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan
EL, et al. Circulating microRNAs as stable blood-based markers for cancer
detection. Proc Natl Acad Sci U S A. 2008;105:10513–8.
13. Xie Y, Todd NW, Liu Z, Zhan M, Fang H, Peng H, et al. Altered miRNA
expression in sputum for diagnosis of non-small cell lung cancer. Lung
Cancer. 2010;67:170–6.
14. Xing L, Todd NW, Yu L, Fang H, Jiang F. Early detection of squamous cell
lung cancer in sputum by a panel of microRNA markers. Mod Pathol.
2010;23:1157–64.
15. Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, et al. Early detection of lung
adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer.
2010;127:2870–8.
16. Shen J, Liao J, Guarnera MA, Fang H, Cai L, Stass SA, et al. Analysis of
MicroRNAs in sputum to improve computed tomography for lung cancer
diagnosis. J Thorac Oncol. 2014;9:33–40.
17. Xing L, Su J, Guarnera MA, Zhang H, Cai L, Zhou R, et al. Sputum microRNA
biomarkers for identifying lung cancer in indeterminate solitary pulmonary
nodules. Clin Cancer Res. 2015;21:484–9.
18. Romeo MS, Sokolova IA, Morrison LE, Zeng C, Baron AE, Hirsch FR, et al.
Chromosomal abnormalities in non-small cell lung carcinomas and in
bronchial epithelia of high-risk smokers detected by multi-target interphase
fluorescence in situ hybridization. J Mol Diagn. 2003;5:103–12.
19. Varella-Garcia M, Kittelson J, Schulte AP, Vu KO, Wolf HJ, Zeng C, et al. Multi-
target interphase fluorescence in situ hybridization assay increases sensitivity of
sputum cytology as a predictor of lung cancer. Cancer Detect Prev.
2004;28:244–51.
20. Yu L, Shen J, Mannoor K, Guarnera M, Jiang F. Identification of ENO1 as a
potential sputum biomarker for early-stage lung cancer by shotgun
proteomics. Clin Lung Cancer. 2014;15:372–8. e1.
21. Li N, Ma J, Guarnera MA, Fang H, Cai L, Jiang F. Digital PCR quantification of
miRNAs in sputum for diagnosis of lung cancer. J Cancer Res Clin Oncol.
2014;140:145–50.
22. Anjuman N, Li N, Guarnera M, Stass SA, Jiang F. Evaluation of lung flute in
sputum samples for molecular analysis of lung cancer. Clin Transl Med.
2013;2:15.
23. Jiang F, Todd NW, Li R, Zhang H, Fang H, Stass SA. A panel of sputum-
based genomic marker for early detection of lung cancer. Cancer Prev Res
(Phila). 2010;3:1571–8.
24. Jiang F, Todd NW, Qiu Q, Liu Z, Katz RL, Stass SA. Combined genetic
analysis of sputum and computed tomography for noninvasive diagnosis of
non-small-cell lung cancer. Lung Cancer. 2009;66:58–63.
25. Katz RL, Zaidi TM, Fernandez RL, Zhang J, He W, Acosta C, et al. Automated
detection of genetic abnormalities combined with cytology in sputum is a
sensitive predictor of lung cancer. Mod Pathol. 2008;21:950–60.
26. Qiu Q, Todd NW, Li R, Peng H, Liu Z, Yfantis HG, et al. Magnetic enrichment
of bronchial epithelial cells from sputum for lung cancer diagnosis.
Cancer. 2008;114:275–83.
27. Li R, Todd NW, Qiu Q, Fan T, Zhao RY, Rodgers WH, et al. Genetic deletions
in sputum as diagnostic markers for early detection of stage I non-small cell
lung cancer. Clin Cancer Res. 2007;13:482–7.
28. Saccomanno G, Saunders RP, Archer VE, Auerbach O, Kuschner M, Beckler
PA. Cancer of the lung: the cytology of sputum prior to the development of
carcinoma. Acta Cytol. 1965;9:413–23.
29. Hubers AJ, van der Drift MA, Prinsen CF, Witte BI, Wang Y, Shivapurkar N,
et al. Methylation analysis in spontaneous sputum for lung cancer
diagnosis. Lung Cancer. 2014;84:127–33.
30. Su J, Liao J, Gao L, Shen J, Guarnera MA, Zhan M, et al. Analysis of small
nucleolar RNAs in sputum for lung cancer diagnosis. Oncotarget.
2015;87:128–36.
31. Bohning D. Youden’s index and the likelihood ratio positive in diagnostic
testing. Methods Inf Med. 2015;54:382–3.32. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al.
Global strategy for the diagnosis, management, and prevention of chronic
obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit
Care Med. 2013;187:347–65.
33. Wang S, Hu J, Zhang D, Li J, Fei Q, Sun Y. Prognostic role of microRNA-31 in
various cancers: a meta-analysis. Tumour Biol. 2014;35:11639–45.
34. Chang W, Lee CY, Park JH, Park MS, Maeng LS, Yoon CS, et al. Survival of
hypoxic human mesenchymal stem cells is enhanced by a positive
feedback loop involving miR-210 and hypoxia-inducible factor 1. J Vet Sci.
2013;14:69–76.
35. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al.
Detection of elevated levels of tumour-associated microRNAs in serum of
patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672–5.
36. Papaconstantinou IG, Manta A, Gazouli M, Lyberopoulou A, Lykoudis PM,
Polymeneas G, et al. Expression of microRNAs in patients with pancreatic
cancer and its prognostic significance. Pancreas. 2013;42:67–71.
37. Hesson LB, Cooper WN, Latif F. Evaluation of the 3p21.3 tumour-suppressor
gene cluster. Oncogene. 2007;26:7283–301.
38. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic
inactivation of a RAS association domain family protein from the lung
tumour suppressor locus 3p21.3. Nat Genet. 2000;25:315–9.
39. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci.
2007;120:3163–72.
40. Liu J, Shworak NW, Sinay P, Schwartz JJ, Zhang L, Fritze LM, et al. Expression
of heparan sulfate D-glucosaminyl 3-O-sulfotransferase isoforms reveals
novel substrate specificities. J Biol Chem. 1999;274:5185–92.
41. Chen H, Zhang C, Sheng Y, Yao S, Liu Z, Zhang T. Frequent SOCS3 and
3OST2 promoter methylation and their epigenetic regulation in endometrial
carcinoma. Am J Cancer Res. 2015;5:180–90.
42. Hubers AJ, Brinkman P, Boksem RJ, Rhodius RJ, Witte BI, Zwinderman AH,
et al. Combined sputum hypermethylation and eNose analysis for lung
cancer diagnosis. J Clin Pathol. 2014;67:707–11.
43. Katz RL, He W, Khanna A, Fernandez RL, Zaidi TM, Krebs M, et al. Genetically
abnormal circulating cells in lung cancer patients: an antigen-independent
fluorescence in situ hybridization-based case-control study. Clin Cancer Res.
2010;16:3976–87.
44. Li R, Wang H, Bekele BN, Yin Z, Caraway NP, Katz RL, et al. Identification of
putative oncogenes in lung adenocarcinoma by a comprehensive
functional genomic approach. Oncogene. 2006;25:2628–35.
45. Jiang F, Caraway NP, Nebiyou Bekele B, Zhang HZ, Khanna A, Wang H, et al.
Surfactant protein A gene deletion and prognostics for patients with stage I
non-small cell lung cancer. Clin Cancer Res. 2005;11:5417–24.
46. Jiang F, Yin Z, Caraway NP, Li R, Katz RL. Genomic profiles in stage I primary
non-small cell lung cancer using comparative genomic hybridization
analysis of cDNA microarrays. Neoplasia. 2004;6:623–35.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
